secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001193125-25-228317
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics elects Brian Posner as Class III director
-----------------------------------------------------------

- Brian Posner elected to Board effective Oct 1, 2025; term runs until 2026 annual meeting.
- Posner deemed independent under Nasdaq rules; no committee appointments.
- Received option to purchase 70,000 shares at $12.50 strike, vesting monthly over three years.
- Annual cash compensation of $45,000 plus standard equity grants under director program.
- No family relationships or transactions with company officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525228317/0001193125-25-228317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525228317/dyn-20251001.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-228317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer